Chinese clinical oncology
-
Chinese clinical oncology · Feb 2016
The supportive care needs for prostate cancer patients in Sarawak.
This cross-sectional study aimed to determine the prevalence of unmet supportive care needs among prostate cancer patients. ⋯ Healthcare providers should provide more responsive, emotionally sensitive and client-centered care to patients with prostate cancer, particularly in the area of Health System and Information, and psychological support.
-
Chinese clinical oncology · Dec 2015
Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
A retrospective monocentric study of consecutive patients with superior sulcus tumor non-small cell lung cancer (SS-NSCLC), treated by induction concurrent chemoradiotherapy (CRT), article management. ⋯ This trimodality treatment regimen confers a survival outcome in agreement with previous studies. Patients with pretreatment N3 lymph node should be included in trimodality treatment.
-
Chinese clinical oncology · Dec 2015
Randomized Controlled TrialProphylactic tracheotomy and lung cancer resection in patient with low predictive pulmonary function: a randomized clinical trials.
Whether prophylactic tracheotomy can shorten the duration of mechanical ventilation (MV) in high risk patients eligible for lung cancer resection. The objective was to compare duration of MV and outcome in 39 patients randomly assigned to prophylactic tracheotomy or control. ⋯ Prophylactic tracheotomy in patients with ppo FEV1 <50% who underwent thoracotomy for lung cancer resection provided benefits in terms of duration of prolonged MV and respiratory complications but was not associated with a decreased mortality rate, ICU and hospital length of stay and non-respiratory complications.
-
Chinese clinical oncology · Dec 2015
ReviewUpcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
For decades, immunotherapy strategies have failed to succeed in lung cancer. However, the recent success of immune checkpoint inhibitors and the progress in the understanding of the immunobiology of lung cancer have changed this paradigm. Here we review ongoing clinical trials and recent results obtained with these novel lung cancer immunotherapies.